Dec 21, 2023 |
DMK Pharmaceuticals Regains Full Rights to Commercialize ZIMHI
|
|
Nov 28, 2023 |
DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
|
|
Nov 14, 2023 |
DMK Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Nov 13, 2023 |
DMK Pharmaceuticals Announces Presentation of Preclinical Results Comparing Effects of DPI-125 on Opioid Withdrawal Behaviors Versus Standard of Care for Opioid Use Disorder at SfN Neuroscience 2023
|
|
Oct 30, 2023 |
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 20, 2023 |
DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 19, 2023 |
DMK Pharmaceuticals Restructures Executive Team to Support Next Phase of Growth
|
|
Sep 07, 2023 |
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
|
|
Aug 21, 2023 |
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 04, 2023 |
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
|
|